Loading...
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib mig...
Na minha lista:
| Udgivet i: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger AG
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4748772/ https://ncbi.nlm.nih.gov/pubmed/26933419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000443662 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|